Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis

Authors: Scott Micek, Michael T Johnson, Richard Reichley, Marin H Kollef

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

Prior antibiotic exposure has been associated with the emergence of antibiotic resistance in subsequent bacterial infections, whose outcomes are typically worse than similar infections with more antibiotic susceptible infections. The influence of prior antibiotic exposure on hospital length of stay (LOS) and costs in patients with severe sepsis or septic shock attributed to Gram-negative bacteremia has not been previously examined.

Methods

A retrospective cohort study of hospitalized patients (January 2002-December 2007) was performed at Barnes-Jewish Hospital, a 1200-bed urban teaching hospital. Patients with Gram-negative bacteremia complicated by severe sepsis or septic shock had data abstraction from computerized medical records. We examined a consecutive cohort of 754 subjects (mean age 59.3 ± 16.3 yrs, mean APACHE II 23.7 ± 6.7).

Results

Escherichia coli (30.8%), Klebsiella pneumoniae (23.2%), and Pseudomonas aeruginosa (17.6%) were the most common organisms isolated from blood cultures. 310 patients (41.1%) had exposure to antimicrobial agents in the previous 90 days. Patients with recent antibiotic exposure had greater inappropriate initial antimicrobial therapy (45.4% v. 21.2%; p < 0.001) and hospital mortality (51.3% v. 34.0%; p < 0.001) compared to patients without recent antibiotic exposure. The unadjusted median LOS (25th percentile, 75th percentile) following sepsis onset in patients with prior antimicrobial exposure was 13.0 days (5.0 days, 24.0 days) compared to 8.0 days (5.0 days, 14.0 days) in those without prior antimicrobial exposure (p < 0.001). In a Cox model controlling for multiple confounders, prior antibiotic exposure independently correlated with remaining hospitalized (Adjusted hazard ratio: 1.473, 95% CI: 1.297-1.672, p < 0.001). Adjusting for potential confounders indicated that prior antibiotic exposure independently increased median attributable LOS by 5.0 days. Similarly, total hospital costs following sepsis onset was significantly greater among patients with prior antimicrobial exposure (median values: $94,737 v. $21,329; p < 0.001).

Conclusions

Recent antibiotic exposure is associated with increased LOS and hospital costs in Gram-negative bacteremia complicated by severe sepsis or septic shock. Clinicians and hospital administrators should consider the potential impact of recent antibiotic exposure when formulating empiric treatment decisions for patients with serious infections attributed to Gram-negative bacteria.
Appendix
Available only for authorised users
Literature
1.
go back to reference Maragakis LL, Perencevich EN, Cosgrove SE: Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008, 6: 751-763. 10.1586/14787210.6.5.751.CrossRefPubMed Maragakis LL, Perencevich EN, Cosgrove SE: Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008, 6: 751-763. 10.1586/14787210.6.5.751.CrossRefPubMed
2.
go back to reference Miyakis S, Pefanis A, Tsakris A: The challenges of antimicrobial resistance in Greece. Clin Infect Dis. 2011, 53: 177-184. 10.1093/cid/cir323.CrossRefPubMed Miyakis S, Pefanis A, Tsakris A: The challenges of antimicrobial resistance in Greece. Clin Infect Dis. 2011, 53: 177-184. 10.1093/cid/cir323.CrossRefPubMed
3.
go back to reference Shorr A, Micek ST, Kollef MH: Inappropriate therapy for methicillin-resistant Staphylococcus aureu: resource utilization and cost implications. Crit Care Med. 2008, 36: 2335-2340. 10.1097/CCM.0b013e31818103ea.CrossRefPubMed Shorr A, Micek ST, Kollef MH: Inappropriate therapy for methicillin-resistant Staphylococcus aureu: resource utilization and cost implications. Crit Care Med. 2008, 36: 2335-2340. 10.1097/CCM.0b013e31818103ea.CrossRefPubMed
4.
go back to reference Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, Shorr AF: Inappropriate empiric antifungal therapy for Candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis. 2010, 10: 150-10.1186/1471-2334-10-150.CrossRefPubMedPubMedCentral Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, Shorr AF: Inappropriate empiric antifungal therapy for Candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis. 2010, 10: 150-10.1186/1471-2334-10-150.CrossRefPubMedPubMedCentral
5.
go back to reference Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH: Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011, 39: 46-51. 10.1097/CCM.0b013e3181fa41a7.CrossRefPubMed Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH: Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011, 39: 46-51. 10.1097/CCM.0b013e3181fa41a7.CrossRefPubMed
6.
go back to reference Shorr AF, Micek ST, Jackson WL: Kollef MH: Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?. Crit Care Med. 2007, 35: 1257-1262. 10.1097/01.CCM.0000261886.65063.CC.CrossRefPubMed Shorr AF, Micek ST, Jackson WL: Kollef MH: Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?. Crit Care Med. 2007, 35: 1257-1262. 10.1097/01.CCM.0000261886.65063.CC.CrossRefPubMed
7.
go back to reference Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999, 115: 462-474. 10.1378/chest.115.2.462.CrossRefPubMed Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999, 115: 462-474. 10.1378/chest.115.2.462.CrossRefPubMed
8.
go back to reference Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med. 2003, 31: 2291-2301. 10.1097/01.CCM.0000085089.88077.AF.CrossRefPubMed Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med. 2003, 31: 2291-2301. 10.1097/01.CCM.0000085089.88077.AF.CrossRefPubMed
9.
go back to reference Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003, 31: 2742-2751. 10.1097/01.CCM.0000098031.24329.10.CrossRefPubMed Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003, 31: 2742-2751. 10.1097/01.CCM.0000098031.24329.10.CrossRefPubMed
10.
go back to reference Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003, 115: 529-535. 10.1016/j.amjmed.2003.07.005.CrossRefPubMed Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003, 115: 529-535. 10.1016/j.amjmed.2003.07.005.CrossRefPubMed
11.
go back to reference Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM: Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med. 2009, 180: 861-866. 10.1164/rccm.200812-1912OC.CrossRefPubMed Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM: Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med. 2009, 180: 861-866. 10.1164/rccm.200812-1912OC.CrossRefPubMed
12.
go back to reference Arias CA, Murray BE: Antibiotic-resistant bugs in the 21st century- a clinical super-challenge. N Engl J Med. 2009, 360: 439-443. 10.1056/NEJMp0804651.CrossRefPubMed Arias CA, Murray BE: Antibiotic-resistant bugs in the 21st century- a clinical super-challenge. N Engl J Med. 2009, 360: 439-443. 10.1056/NEJMp0804651.CrossRefPubMed
13.
go back to reference Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48: 1-12. 10.1086/595011.CrossRefPubMed Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48: 1-12. 10.1086/595011.CrossRefPubMed
14.
go back to reference Kollef MH: Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008, 47: S3-S13. 10.1086/590061.CrossRefPubMed Kollef MH: Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008, 47: S3-S13. 10.1086/590061.CrossRefPubMed
15.
go back to reference Barochia AV, Cui X, Vitberg D, Suffredini AF, O'Grady NP, Banks SM, Minneci P, Kern SJ, Danner RL, Natanson C, Eichacker PQ: Bundled care for septic shock: an analysis of clinical trials. Crit Care Med. 2010, 38: 668-678. 10.1097/CCM.0b013e3181cb0ddf.CrossRefPubMedPubMedCentral Barochia AV, Cui X, Vitberg D, Suffredini AF, O'Grady NP, Banks SM, Minneci P, Kern SJ, Danner RL, Natanson C, Eichacker PQ: Bundled care for septic shock: an analysis of clinical trials. Crit Care Med. 2010, 38: 668-678. 10.1097/CCM.0b013e3181cb0ddf.CrossRefPubMedPubMedCentral
16.
go back to reference Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008, 36: 296-327. 10.1097/01.CCM.0000298158.12101.41.CrossRefPubMed Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008, 36: 296-327. 10.1097/01.CCM.0000298158.12101.41.CrossRefPubMed
17.
go back to reference Johnson MT, Reichley R, Hoppe-Bauer J, Dunne WM, Micek S, Kollef M: Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med. 2011, 39: 1859-1865. 10.1097/CCM.0b013e31821b85f4.CrossRefPubMed Johnson MT, Reichley R, Hoppe-Bauer J, Dunne WM, Micek S, Kollef M: Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med. 2011, 39: 1859-1865. 10.1097/CCM.0b013e31821b85f4.CrossRefPubMed
18.
go back to reference Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13: 818-829. 10.1097/00003246-198510000-00009.CrossRefPubMed Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13: 818-829. 10.1097/00003246-198510000-00009.CrossRefPubMed
19.
go back to reference Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002.CrossRefPubMed Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002.CrossRefPubMed
20.
go back to reference National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. M100-S12. 2002, National Committee for Clinical Laboratory Standards, Wayne, PA National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. M100-S12. 2002, National Committee for Clinical Laboratory Standards, Wayne, PA
21.
go back to reference Clinical Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. M100-S17. 2007, Clinical Laboratory Standards Institute, Wayne, PA Clinical Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. M100-S17. 2007, Clinical Laboratory Standards Institute, Wayne, PA
22.
go back to reference Webster DP, Young BC, Morton R, Collyer D, Batchelor B, Turton JF, Maharjan S, Livermore DM, Bejon P, Cookson BD, Bowler IC: Impact of a clonal outbreak of extended-spectrum {beta}-lactamase-producing Klebsiella pneumonia in the development and evolution of bloodstream infections by K. pneumonia and Escherichia col an 11 year experience in Oxfordshire, UK. J Antimicrob Chemother. 2011, 66: 2126-2135. 10.1093/jac/dkr246.CrossRefPubMed Webster DP, Young BC, Morton R, Collyer D, Batchelor B, Turton JF, Maharjan S, Livermore DM, Bejon P, Cookson BD, Bowler IC: Impact of a clonal outbreak of extended-spectrum {beta}-lactamase-producing Klebsiella pneumonia in the development and evolution of bloodstream infections by K. pneumonia and Escherichia col an 11 year experience in Oxfordshire, UK. J Antimicrob Chemother. 2011, 66: 2126-2135. 10.1093/jac/dkr246.CrossRefPubMed
23.
go back to reference Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M: Imipenem resistance in Pseudomonas aeruginos: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010, 31: 47-53. 10.1086/649021.CrossRefPubMed Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M: Imipenem resistance in Pseudomonas aeruginos: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010, 31: 47-53. 10.1086/649021.CrossRefPubMed
24.
go back to reference Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH: Pseudomonas aeruginos bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005, 49: 1306-1311. 10.1128/AAC.49.4.1306-1311.2005.CrossRefPubMedPubMedCentral Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH: Pseudomonas aeruginos bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005, 49: 1306-1311. 10.1128/AAC.49.4.1306-1311.2005.CrossRefPubMedPubMedCentral
25.
go back to reference Johnson SJ, Ernst EJ, Moores KG: Is double coverage of gram-negative organisms necessary?. Am J Health Syst Pharm. 2011, 68: 119-124. 10.2146/ajhp090360.CrossRefPubMed Johnson SJ, Ernst EJ, Moores KG: Is double coverage of gram-negative organisms necessary?. Am J Health Syst Pharm. 2011, 68: 119-124. 10.2146/ajhp090360.CrossRefPubMed
Metadata
Title
An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis
Authors
Scott Micek
Michael T Johnson
Richard Reichley
Marin H Kollef
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-56

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.